Learn more about Just – Evotec Biologics’ continuous manufacturing platform for biologics in this poster. The platform is ideal for first-in-human and early-phase clinical trials with antibody biotherapeutics.

Learnings from the poster:

• Clinical programs are initiated with the most productive process possible with no need for subsequent optimization
• Scale-up is not required as the same equipment is used for early-phase clinical supply, late-phase clinical and Phase III supply as well as commercial manufacturing of biologics without changing facility
• Manufacturing for first-in-human (FIH) programs can take place at our biomanufacturing facilities in either Seattle, WA or Toulouse, France. Either way, manufacturing is close to US and European sponsor companies.
• Just – Evotec Biologics has a strong track record of filing INDs with different health authorities

Learn more about Just – Evotec Biologics services around first-in-human programs here